Trial Profile

A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis: AMVISION-1

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 21 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Brodalumab (Primary)
Indications Psoriatic arthritis
Focus Registrational; Therapeutic Use
Acronyms AMVISION-1
Sponsors Amgen; Bausch Health Companies

Most Recent Events

16 Dec 2021 This trial has been completed in France, according to European Clinical Trials Database record.
26 Oct 2020 Primary endpoint (American College of Rheumatology (ACR) 20 response) has been met according to the results published in the Annals of the Rheumatic Diseases
26 Oct 2020 Pooled analysis results from AMVISION-1 and AMVISION-2 studies were published in the Annals of the Rheumatic Diseases

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com